Terumo（TRUM.F）株式概要テルモ株式会社は、日本、欧州、中国、米国、アジア、および国際的な医療製品・機器の製造・販売を行っています。 詳細TRUM.F ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長1/6過去の実績5/6財務の健全性6/6配当金5/6報酬当社が推定した公正価値より12.6%で取引されている 収益は年間11.94%増加すると予測されています 過去1年間で収益は16.2%増加しました 1.58%の安定した配当金を支払う アナリストらは、株価が30.3%上昇するだろうとほぼ一致している。 リスク分析株式の流動性は非常に低い すべてのリスクチェックを見るTRUM.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$14.9616.0% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture02t2016201920222025202620282031Revenue JP¥1.5tEarnings JP¥183.9bAdvancedSet Fair ValueView all narrativesTerumo Corporation 競合他社STERISSymbol: NYSE:STEMarket cap: US$20.5bResMedSymbol: NYSE:RMDMarket cap: US$27.9bZimmer Biomet HoldingsSymbol: NYSE:ZBHMarket cap: US$16.9bDexComSymbol: NasdaqGS:DXCMMarket cap: US$29.6b価格と性能株価の高値、安値、推移の概要Terumo過去の株価現在の株価JP¥14.9652週高値JP¥20.4652週安値JP¥11.49ベータ0.211ヶ月の変化11.23%3ヶ月変化20.94%1年変化-24.97%3年間の変化-8.70%5年間の変化-28.73%IPOからの変化78.94%最新ニュースお知らせ • May 15Terumo Corporation, Annual General Meeting, Jun 26, 2026Terumo Corporation, Annual General Meeting, Jun 26, 2026.お知らせ • Apr 02Terumo Corporation to Report Q4, 2026 Results on May 15, 2026Terumo Corporation announced that they will report Q4, 2026 results on May 15, 2026お知らせ • Dec 17Terumo Corporation to Report Q3, 2026 Results on Feb 13, 2026Terumo Corporation announced that they will report Q3, 2026 results on Feb 13, 2026お知らせ • Nov 12+ 1 more updateTerumo Corporation Announces Dividend for the Second Quarter End of 2026, Payable on December 2, 2025; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026Terumo Corporation announced dividend for the second quarter end of 2026, payable on December 2, 2025; provided dividend guidance for the Fiscal year ending March 31, 2026. For the quarter, the company announced dividend of JPY 15.00 per share compared to JPY 13.00 per share a year ago. For the year, the company expects dividend of JPY 15.00 per share compared to JPY 13.00 per share a year ago.お知らせ • Oct 30Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire remaining 99.5% stake in OrganOx Limited from a group of shareholders for $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The transaction will be funded from cash on hand and borrowings. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. The transaction is expected to close in FY2025. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Robbie McLaren, Ross McAloon, Charles Ruck, Elizabeth Richards, Betty Pang, Chad Jennings, Sean Finn, Maj Vaseghi, Kendall Burnett, Hector Armengod, Patrick English, Catherine Hein and Philipp Studt of Latham & Watkins acted as legal counsel to OrganOx in this transaction. Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders on October 29, 2025.お知らせ • Oct 24Terumo Interventional Systems Announces its New OPUSWAVE Dual Sensor Imaging System and DualView®? Imaging Catheter Receive FDA 510(k) ClearanceTerumo Interventional Systems (TIS) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its OPUSWAVE®? Dual Sensor Imaging System. The OPUSWAVE Imaging System features the DualView®? imaging catheter, which also received FDA 510(k) clearance. The OPUSWAVE imaging System combines Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) to enable simultaneous views, offering physicians the ability to comprehensively evaluate coronary artery disease (CAD). While this marks Terumo's imaging debut in the US market, the company is already a recognized leader in the single modality imaging space in Japan, where adoption of imaging in percutaneous coronary intervention (PCI) procedures is the highest in the world. What makes the OPUSWAVE Imaging System unique is the DualView imaging catheter, which offers a 150mm maximum pullback length. It also has a 2.6 Fr. imaging profile, 6 Fr. guide compatibility, advanced hydrophilic coating, and a variable pullback speed of up to 40mm/second in dual mode.最新情報をもっと見るRecent updatesお知らせ • May 15Terumo Corporation, Annual General Meeting, Jun 26, 2026Terumo Corporation, Annual General Meeting, Jun 26, 2026.お知らせ • Apr 02Terumo Corporation to Report Q4, 2026 Results on May 15, 2026Terumo Corporation announced that they will report Q4, 2026 results on May 15, 2026お知らせ • Dec 17Terumo Corporation to Report Q3, 2026 Results on Feb 13, 2026Terumo Corporation announced that they will report Q3, 2026 results on Feb 13, 2026お知らせ • Nov 12+ 1 more updateTerumo Corporation Announces Dividend for the Second Quarter End of 2026, Payable on December 2, 2025; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026Terumo Corporation announced dividend for the second quarter end of 2026, payable on December 2, 2025; provided dividend guidance for the Fiscal year ending March 31, 2026. For the quarter, the company announced dividend of JPY 15.00 per share compared to JPY 13.00 per share a year ago. For the year, the company expects dividend of JPY 15.00 per share compared to JPY 13.00 per share a year ago.お知らせ • Oct 30Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire remaining 99.5% stake in OrganOx Limited from a group of shareholders for $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The transaction will be funded from cash on hand and borrowings. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. The transaction is expected to close in FY2025. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Robbie McLaren, Ross McAloon, Charles Ruck, Elizabeth Richards, Betty Pang, Chad Jennings, Sean Finn, Maj Vaseghi, Kendall Burnett, Hector Armengod, Patrick English, Catherine Hein and Philipp Studt of Latham & Watkins acted as legal counsel to OrganOx in this transaction. Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders on October 29, 2025.お知らせ • Oct 24Terumo Interventional Systems Announces its New OPUSWAVE Dual Sensor Imaging System and DualView®? Imaging Catheter Receive FDA 510(k) ClearanceTerumo Interventional Systems (TIS) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its OPUSWAVE®? Dual Sensor Imaging System. The OPUSWAVE Imaging System features the DualView®? imaging catheter, which also received FDA 510(k) clearance. The OPUSWAVE imaging System combines Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) to enable simultaneous views, offering physicians the ability to comprehensively evaluate coronary artery disease (CAD). While this marks Terumo's imaging debut in the US market, the company is already a recognized leader in the single modality imaging space in Japan, where adoption of imaging in percutaneous coronary intervention (PCI) procedures is the highest in the world. What makes the OPUSWAVE Imaging System unique is the DualView imaging catheter, which offers a 150mm maximum pullback length. It also has a 2.6 Fr. imaging profile, 6 Fr. guide compatibility, advanced hydrophilic coating, and a variable pullback speed of up to 40mm/second in dual mode.お知らせ • Sep 19Terumo Corporation to Report Q2, 2026 Results on Nov 12, 2025Terumo Corporation announced that they will report Q2, 2026 results on Nov 12, 2025お知らせ • Aug 25Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Latham & Watkins acted as legal counsel to OrganOx in this transaction.お知らせ • Jun 24Terumo Corporation to Report Q1, 2026 Results on Aug 07, 2025Terumo Corporation announced that they will report Q1, 2026 results on Aug 07, 2025お知らせ • Jun 03Terumo Neuro Announces EMEA Commercial Availability of the SOFIA™? Flow 88 Neurovascular Aspiration CatheterTerumo Neuro announced the commercial availability of the SOFIA Flow 88 Neurovascular Aspiration Catheter, expanding the company's stroke portfolio with a new large-bore catheter engineered for reliability, procedural flexibility, and physician control. The launch builds on the proven clinical performance and global legacy of the SOFIA™? Catheter line, which has supported more than 500,000 procedures across 170 countries over the past decade. Terumo Neuro is showcasing its complete line of stroke solutions at LINNC Paris this week at Le Carrousel du Louvre, booth number 8. Leveraging more than ten years of neurovascular catheter innovation, physician partnerships and proven clinical performance1-9, the SOFIA™? 88 Neurovascular As inspiration Catheter offers an 0.088-inch inner diameter with proprietary engineering enhancements designed to provide the following benefits: Reach with Confidence - Reliable trackability through challenging anatomy via optimized transition zones and a soft, atraumatic distal tip. Support to Go the Distance - Proximal stability for procedural ease with both short and long sheaths. Atraumatic by Design - Flexibility and reinforcement throughout the entire working length to minimize vessel trauma and support smooth navigation. Engage the Clot with Confidence - Highly compliant proprietary SOFIA tip beyond the marker band expands conforming to the clot. Aspirate with Confidence - Next generation SOFIA technology with nitinol braid and coil reinforcement maintains lumen integrity. The SOFIA™ 88 Neurovascular Aspiration Catheter is compatible with the SOFIA™ Plus 6F Aspiration Catheter and supports integration into existing aspiration strategies. Clinical evidence from the SOFAST registry & the SESAME trial—evaluating the SOFIA™ Plus 6F as a first-line approach—demonstrated strong results across speed, efficacy, and safety and overall clinical outcomes. The new SOFIA™ 88 Catheter also seamlessly complements the company's broader stroke solution portfolio, offering a fully integrated approach across aspiration, access, retrieval, and navigation: SOFIA™ and SOFIA™ Plus Aspiration Catheters – Renowned for trackability and clinical performance, ERIC™ Retrieval Device – Designed for thrombus control, procedural efficiency, and versatility, BOBBY™ Balloon Guide Catheter – Reliable flow arrest with streamlined preparation, optimized compatibility and next-generation balloon technology, WEDGE™ Microcatheter – A navigation aid that minimizes ledge effect, HEADWAY™ Microcatheters – Low-profile outer diameter, providing versatility, reliability, and fast access, and TRAXCESS™ Guidewires – Soft-tip design for challenging anatomies.お知らせ • May 28Terumo Interventional Systems, Division of Terumo Corporation, Announces Commercial Availability of its ROADSAVER Carotid Stent SystemTerumo Interventional Systems (TIS), a division of Terumo Corporation, announced the early commercial availability of its FDA-approved ROADSAVER Carotid Stent System. Indicated for use with the Nanoparasol®? Embolic Protection System, ROADSAVER Stent System addresses carotid artery stenosis in patients with increased risk of adverse events following carotid endarterectomy. ROADSAver Stent System is the only carotid artery stenting (CAS) device with an innovative, dual-layer micromesh. It is designed as a closed-cell stent with the flexibility of an open-cell stent, providing increased flexibility and wall apposition in complex anatomies. It is also the first dual-layer micromesh carotid stent approved in the United States, and the only carotid stent system designed to contain plaque to the vessel wall and prevent plaque protrusion, protecting against distal embolization. Available in sizes from 5 to 10 mm in width and 22 to 47 mm in length, ROADSAVER StENT System has a rapid-exchange shaft length of 143 cm. It is also fully re-sheathable and repositionable - even after 50% of the stent's length is deployed. Another important feature is the product's low-profile 5Fr design, which enhances its crossability. Limited market release of the ROADSAVER CarotID Stent System is planned for summer 2025, with full market release anticipated in fall 2025.お知らせ • May 14Terumo Corporation, Annual General Meeting, Jun 24, 2025Terumo Corporation, Annual General Meeting, Jun 24, 2025.お知らせ • Apr 17Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business OfficerTerumo Blood and Cell Technologies (Terumo BCT) announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments. Daly joins Terumo BCT with over 30 years of business and healthcare industry experience, both domestically and internationally. Most recently, he built the MedTech Global Data franchise at IQVIA, a provider of technology solutions to the life sciences industry. Daly has spent his career building commercial capabilities to deliver organic and inorganic growth. Before joining IQVIA, he was President and CEO of Cohera Medical, and he remains an independent Board Director for BioStem Technologies. He has held successive senior leadership roles in strategic marketing, sales and business development across various regions and businesses of Johnson &Johnson. He earned his Bachelor of Science in Foreign Area Studies from the U.S. Military Academy at West Point.お知らせ • Mar 20Terumo Corporation to Report Fiscal Year 2025 Results on May 14, 2025Terumo Corporation announced that they will report fiscal year 2025 results on May 14, 2025お知らせ • Dec 12Terumo Corporation to Report Q3, 2025 Results on Feb 13, 2025Terumo Corporation announced that they will report Q3, 2025 results on Feb 13, 2025お知らせ • Dec 03Terumo Interventional Systems Announces Launch of Its R2p Navicross Peripheral Support CatheterTerumo Interventional Systems (TIS), a division of Terumo Corporation announced the launch and commercial availability of its R2P™ NaviCross® peripheral support catheter in the U.S., further expanding the company's radial-to-peripheral (R2P) portfolio. The R2P NaviCross catheter, now available in a 200 cm length, is designed for optimized performance in R2P procedures. Its double-braided, stainless-steel construction is engineered for superior trackability and torque control for lesion crossing in more complex procedures. The new 200 cm R2P NaviCross catheter rounds out the existing R2P portfolio, including the R2P Destination Slender™ guiding sheath, R2P SlenGuide™ guiding catheter, R2P Misago® self-expanding peripheral stent, and R2P Metacross™ RX and R2P Crosstella™ RX dilatation catheters – giving physicians the confidence to complete almost any PAD procedure from the wrist.お知らせ • Sep 25Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024Terumo Corporation announced that they will report Q2, 2025 results on Nov 07, 2024お知らせ • Aug 30Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million.Terumo Corporation (TSE:4543) announces a share repurchase program. Under the program, the company will repurchase up to 15,000,000 shares, representing 1.01% of its issued share capital, for ¥30,000 million. The purpose of the program is to increase shareholder returns, improve capital efficiency, and mitigate the impact on stock supply and demand associated with the offering of our common stock. The repurchased shares will be cancelled. The program will run until December 30, 2024. As of June 30, 2024, the company had 1,484,855,220 shares in issue (excluding treasury stock) and 5,842,060 shares in treasury.お知らせ • Jun 03Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024Terumo Corporation announced that they will report Q1, 2025 results on Aug 08, 2024お知らせ • May 29Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring SystemTerumo Cardiovascular announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the CDI OneView Monitoring System. The next-generation CDI Systems platform provides visibility of key patient parameters during cardiopulmonary bypass surgery, critical to perfusion safety and improving patient outcomes. The new CDI OneView System measures or displays up to 22 key parameters, the newest of which are measured flow (Q), cardiac index (CI), regional cerebral oxygen saturation (rSO2), oxygen extraction ratio (O2ER), Area Under the DO2 Curve (AUC), and measured arterial oxygen saturation (SaO2). This innovative system offers maximum configurability and flexibility in how the parameters can be viewed and prioritized to best suit clinical needs and preferences, while continuing to provide the critical information on which clinicians have come to rely. New features and functions of Terumo's latest patient parameter monitoring system were influenced by extensive perfusionist input from leading global cardiovascular institutions. In response to the growing needs of healthcare providers, the new CDI OneView System now provides real-time O2ER, CI, VO2 and DO2 information to help perfusionists maintain a safe threshold for those parameters. Independently published and reviewed clinical research indicates that maintaining optimal levels during cardiopulmonary bypass can help to reduce the incidence of acute kidney injury.お知らせ • Mar 17Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024Terumo Corporation announced that they will report fiscal year 2024 results on May 14, 2024お知らせ • Feb 09Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company expects revenue to be JPY 906,000 million. Operating profit to be JPY 140,000 million. Profit attributable to owners of parent to be JPY 105,000 million. Earnings per share to be JPY 141.18.お知らせ • Feb 07Terumo Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation provided dividend guidance for the fiscal year ending March 31, 2024. For the year, the company expects dividend of JPY 22.00 per share against JPY 21.00 per share paid for the same period a year ago.お知らせ • Dec 14+ 2 more updatesShinjiro Sato to Leave as CEO of Terumo Corporation on April 1, 2024Terumo Corporation announced that it has resolved at the Board of Directors held on December 14, 2023 to change the Executive Officers as. Shinjiro Sato's designation will be changed from President and CEO to the new position of Director and Corporate Advisor (As of April 1, 2024). Shinjiro Sato, with completion of his term, is planned to leave the director's position at the Annual General Meeting of Shareholders to be held on June 26, 2024, and to remain as corporate advisor.お知らせ • Dec 03Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024Terumo Corporation announced that they will report Q3, 2024 results on Feb 07, 2024お知らせ • Oct 01Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023Terumo Corporation announced that they will report Q2, 2024 results on Nov 14, 2023お知らせ • Aug 10Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million.Terumo Corporation (TSE:4543) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 shares, representing 0.67% of its issued share capital, for ¥20,000 million. The purpose of the program is to expand shareholder returns and improve capital efficiency. The repurchased shares will be cancelled. The program will run until March 8, 2024. As of June 30, 2023, the company had 744,644,147 shares in issue (excluding treasury stock) and 3,038,393 shares in treasury.お知らせ • Jun 21Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023Terumo Corporation announced that they will report Q1, 2024 results on Aug 09, 2023お知らせ • May 17+ 1 more updateTerumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation announced fiscal year-end dividend of JPY 21.00 per share for the fiscal year ended March 31, 2023 against JPY 18.00 per share paid a year ago. Scheduled date to commence dividend payments is June 28, 2023.The company provided second quarter-end dividend guidance for the fiscal year ending March 31, 2024. For the second quarter-end, The company expects to pay JPY 22.00 against JPY 19.00 per share paid a year ago.The company provided year-end dividend guidance for the fiscal year ending March 31, 2024. For the year-end, The company expects to pay JPY 22.00 against JPY 21.00 per share a year ago.お知らせ • May 16Terumo Corporation, Annual General Meeting, Jun 27, 2023Terumo Corporation, Annual General Meeting, Jun 27, 2023.お知らせ • Feb 09Terumo Corporation Revises Dividend Guidance for Fiscal Year Ending March 31, 2023Terumo Corporation decided at the Board of Directors meeting held on February 9, 2023 to increase the year-end dividend forecast for fiscal year ending March 31, 2023. The details are as follows. The company revised dividend forecast to JPY 21.00 per share compared to the previous guidance of JPY 19.00 per share paid for the same period a year ago. Reason of the Revision: As a measure to secure high profit margins and sustainable growth, Terumo iscommitted to adequately and actively reinvesting its profits to enhance its corporate value continuously. As for the distribution of profits to shareholders, Terumo has been aiming to steadily increase its dividend payouts to shareholders with the target dividend payout ratio of 30% in the mid to long-term.お知らせ • Nov 10Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023Terumo Corporation announced that they will report Q3, 2023 results on Nov 10, 2023お知らせ • Aug 25Terumo Corporation (TSE:4543) acquired ReThink Medical, Inc.Terumo Corporation (TSE:4543) acquired ReThink Medical, Inc. on August 11, 2020. Hiroki Kobayashi of Latham & Watkins LLP acted as the legal advisor to Terumo. Terumo Corporation (TSE:4543) completed the acquisition of ReThink Medical, Inc. on August 11, 2020.お知らせ • Jul 30Terumo Corporation (TSE:4543) acquired remaining 80.1% stake in Quirem Medical B.V. for $45 million.Terumo Corporation (TSE:4543) acquired remaining 80.1% stake in Quirem Medical B.V. for $45 million on July 15, 2020. Terumo will make a one-time, up-front payment of USD 20 million with up to USD 25 million additional payments based on the achievement of future milestones by 2030. It will be funded through cash on hand and will not significantly impact the company's financial projections for the current fiscal year ending March 31, 2021. Terumo Corporation (TSE:4543) completed the acquisition of remaining 80.1% stake in Quirem Medical B.V. on July 15, 2020.お知らせ • Jun 29Terumo Corporation to Report Q1, 2021 Results on Aug 06, 2020Terumo Corporation announced that they will report Q1, 2021 results on Aug 06, 2020株主還元TRUM.FUS Medical EquipmentUS 市場7D10.0%6.1%-3.3%1Y-25.0%-19.2%22.3%株主還元を見る業界別リターン: TRUM.F過去 1 年間で-19.2 % の収益を上げたUS Medical Equipment業界を下回りました。リターン対市場: TRUM.Fは、過去 1 年間で22.3 % のリターンを上げたUS市場を下回りました。価格変動Is TRUM.F's price volatile compared to industry and market?TRUM.F volatilityTRUM.F Average Weekly Movementn/aMedical Equipment Industry Average Movement8.6%Market Average Movement7.2%10% most volatile stocks in US Market16.6%10% least volatile stocks in US Market3.1%安定した株価: TRUM.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のTRUM.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト1921n/aHikaru Samejimawww.terumo.comテルモ株式会社は、日本、欧州、中国、米国、アジア、および国際的な医療製品・機器の製造・販売を行っている。同社は3つのセグメントを通じて事業を展開している：心臓・血管カンパニー、メディカル・ケア・ソリューションズ・カンパニー、血液・細胞テクノロジー・カンパニーの3つである。心臓・血管カンパニーでは、血管造影用ガイドワイヤー、血管造影用カテーテル、イントロデューサーシース、血管閉鎖器具、PTCAバルーンカテーテル、冠動脈ステント、自己拡張型末梢ステント、血管内超音波システム、イメージングカテーテルなどを提供している；脳動脈瘤治療用コイル、ステント、髄腔内デバイス、虚血性脳卒中治療用塞栓システム、吸引カテーテル、血栓回収器など、酸素供給器、心肺バイパスシステムなど、人工血管、ステントグラフトなど。メディカル・ケア・ソリューションズ・カンパニー」セグメントは、注射器、輸液ポンプ、シリンジポンプ、輸液ライン、輸液、腹膜透析液、疼痛管理・栄養食品、接着バリア、その他、血糖値モニタリングシステム、ペン型注射器用ディスポーザブル針、インスリンパッチポンプ、血圧モニター、デジタル体温計、その他、プレフィルドシリンジ、製薬会社向け薬剤キット用デバイスの受託製造、プレフィルドシリンジ、医薬品包装用針、その他を提供している。血液・細胞テクノロジーカンパニー事業は、血液バッグ、成分採取システム、自動血液処理システム、病原体除去システム、遠心アフェレーシスシステム、細胞膨張システムなどを提供している。1974年10月にテルモ株式会社に社名変更。テルモ株式会社は1921年に設立され、東京に本社を置く。もっと見るTerumo Corporation 基礎のまとめTerumo の収益と売上を時価総額と比較するとどうか。TRUM.F 基礎統計学時価総額US$21.06b収益（TTM）US$849.46m売上高(TTM)US$7.07b24.7xPER（株価収益率3.0xP/SレシオTRUM.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計TRUM.F 損益計算書（TTM）収益JP¥1.13t売上原価JP¥534.96b売上総利益JP¥596.91bその他の費用JP¥461.00b収益JP¥135.91b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）92.14グロス・マージン52.74%純利益率12.01%有利子負債／自己資本比率24.0%TRUM.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.6%現在の配当利回り33%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 08:44終値2026/06/05 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Terumo Corporation 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。27 アナリスト機関Steven LiuAletheia Analyst Network LimitedMasahiro NakanomyoBarclaysRitsuo WatanabeBofA Global Research24 その他のアナリストを表示
お知らせ • May 15Terumo Corporation, Annual General Meeting, Jun 26, 2026Terumo Corporation, Annual General Meeting, Jun 26, 2026.
お知らせ • Apr 02Terumo Corporation to Report Q4, 2026 Results on May 15, 2026Terumo Corporation announced that they will report Q4, 2026 results on May 15, 2026
お知らせ • Dec 17Terumo Corporation to Report Q3, 2026 Results on Feb 13, 2026Terumo Corporation announced that they will report Q3, 2026 results on Feb 13, 2026
お知らせ • Nov 12+ 1 more updateTerumo Corporation Announces Dividend for the Second Quarter End of 2026, Payable on December 2, 2025; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026Terumo Corporation announced dividend for the second quarter end of 2026, payable on December 2, 2025; provided dividend guidance for the Fiscal year ending March 31, 2026. For the quarter, the company announced dividend of JPY 15.00 per share compared to JPY 13.00 per share a year ago. For the year, the company expects dividend of JPY 15.00 per share compared to JPY 13.00 per share a year ago.
お知らせ • Oct 30Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire remaining 99.5% stake in OrganOx Limited from a group of shareholders for $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The transaction will be funded from cash on hand and borrowings. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. The transaction is expected to close in FY2025. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Robbie McLaren, Ross McAloon, Charles Ruck, Elizabeth Richards, Betty Pang, Chad Jennings, Sean Finn, Maj Vaseghi, Kendall Burnett, Hector Armengod, Patrick English, Catherine Hein and Philipp Studt of Latham & Watkins acted as legal counsel to OrganOx in this transaction. Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders on October 29, 2025.
お知らせ • Oct 24Terumo Interventional Systems Announces its New OPUSWAVE Dual Sensor Imaging System and DualView®? Imaging Catheter Receive FDA 510(k) ClearanceTerumo Interventional Systems (TIS) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its OPUSWAVE®? Dual Sensor Imaging System. The OPUSWAVE Imaging System features the DualView®? imaging catheter, which also received FDA 510(k) clearance. The OPUSWAVE imaging System combines Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) to enable simultaneous views, offering physicians the ability to comprehensively evaluate coronary artery disease (CAD). While this marks Terumo's imaging debut in the US market, the company is already a recognized leader in the single modality imaging space in Japan, where adoption of imaging in percutaneous coronary intervention (PCI) procedures is the highest in the world. What makes the OPUSWAVE Imaging System unique is the DualView imaging catheter, which offers a 150mm maximum pullback length. It also has a 2.6 Fr. imaging profile, 6 Fr. guide compatibility, advanced hydrophilic coating, and a variable pullback speed of up to 40mm/second in dual mode.
お知らせ • May 15Terumo Corporation, Annual General Meeting, Jun 26, 2026Terumo Corporation, Annual General Meeting, Jun 26, 2026.
お知らせ • Apr 02Terumo Corporation to Report Q4, 2026 Results on May 15, 2026Terumo Corporation announced that they will report Q4, 2026 results on May 15, 2026
お知らせ • Dec 17Terumo Corporation to Report Q3, 2026 Results on Feb 13, 2026Terumo Corporation announced that they will report Q3, 2026 results on Feb 13, 2026
お知らせ • Nov 12+ 1 more updateTerumo Corporation Announces Dividend for the Second Quarter End of 2026, Payable on December 2, 2025; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026Terumo Corporation announced dividend for the second quarter end of 2026, payable on December 2, 2025; provided dividend guidance for the Fiscal year ending March 31, 2026. For the quarter, the company announced dividend of JPY 15.00 per share compared to JPY 13.00 per share a year ago. For the year, the company expects dividend of JPY 15.00 per share compared to JPY 13.00 per share a year ago.
お知らせ • Oct 30Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire remaining 99.5% stake in OrganOx Limited from a group of shareholders for $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The transaction will be funded from cash on hand and borrowings. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. The transaction is expected to close in FY2025. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Robbie McLaren, Ross McAloon, Charles Ruck, Elizabeth Richards, Betty Pang, Chad Jennings, Sean Finn, Maj Vaseghi, Kendall Burnett, Hector Armengod, Patrick English, Catherine Hein and Philipp Studt of Latham & Watkins acted as legal counsel to OrganOx in this transaction. Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders on October 29, 2025.
お知らせ • Oct 24Terumo Interventional Systems Announces its New OPUSWAVE Dual Sensor Imaging System and DualView®? Imaging Catheter Receive FDA 510(k) ClearanceTerumo Interventional Systems (TIS) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its OPUSWAVE®? Dual Sensor Imaging System. The OPUSWAVE Imaging System features the DualView®? imaging catheter, which also received FDA 510(k) clearance. The OPUSWAVE imaging System combines Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) to enable simultaneous views, offering physicians the ability to comprehensively evaluate coronary artery disease (CAD). While this marks Terumo's imaging debut in the US market, the company is already a recognized leader in the single modality imaging space in Japan, where adoption of imaging in percutaneous coronary intervention (PCI) procedures is the highest in the world. What makes the OPUSWAVE Imaging System unique is the DualView imaging catheter, which offers a 150mm maximum pullback length. It also has a 2.6 Fr. imaging profile, 6 Fr. guide compatibility, advanced hydrophilic coating, and a variable pullback speed of up to 40mm/second in dual mode.
お知らせ • Sep 19Terumo Corporation to Report Q2, 2026 Results on Nov 12, 2025Terumo Corporation announced that they will report Q2, 2026 results on Nov 12, 2025
お知らせ • Aug 25Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Latham & Watkins acted as legal counsel to OrganOx in this transaction.
お知らせ • Jun 24Terumo Corporation to Report Q1, 2026 Results on Aug 07, 2025Terumo Corporation announced that they will report Q1, 2026 results on Aug 07, 2025
お知らせ • Jun 03Terumo Neuro Announces EMEA Commercial Availability of the SOFIA™? Flow 88 Neurovascular Aspiration CatheterTerumo Neuro announced the commercial availability of the SOFIA Flow 88 Neurovascular Aspiration Catheter, expanding the company's stroke portfolio with a new large-bore catheter engineered for reliability, procedural flexibility, and physician control. The launch builds on the proven clinical performance and global legacy of the SOFIA™? Catheter line, which has supported more than 500,000 procedures across 170 countries over the past decade. Terumo Neuro is showcasing its complete line of stroke solutions at LINNC Paris this week at Le Carrousel du Louvre, booth number 8. Leveraging more than ten years of neurovascular catheter innovation, physician partnerships and proven clinical performance1-9, the SOFIA™? 88 Neurovascular As inspiration Catheter offers an 0.088-inch inner diameter with proprietary engineering enhancements designed to provide the following benefits: Reach with Confidence - Reliable trackability through challenging anatomy via optimized transition zones and a soft, atraumatic distal tip. Support to Go the Distance - Proximal stability for procedural ease with both short and long sheaths. Atraumatic by Design - Flexibility and reinforcement throughout the entire working length to minimize vessel trauma and support smooth navigation. Engage the Clot with Confidence - Highly compliant proprietary SOFIA tip beyond the marker band expands conforming to the clot. Aspirate with Confidence - Next generation SOFIA technology with nitinol braid and coil reinforcement maintains lumen integrity. The SOFIA™ 88 Neurovascular Aspiration Catheter is compatible with the SOFIA™ Plus 6F Aspiration Catheter and supports integration into existing aspiration strategies. Clinical evidence from the SOFAST registry & the SESAME trial—evaluating the SOFIA™ Plus 6F as a first-line approach—demonstrated strong results across speed, efficacy, and safety and overall clinical outcomes. The new SOFIA™ 88 Catheter also seamlessly complements the company's broader stroke solution portfolio, offering a fully integrated approach across aspiration, access, retrieval, and navigation: SOFIA™ and SOFIA™ Plus Aspiration Catheters – Renowned for trackability and clinical performance, ERIC™ Retrieval Device – Designed for thrombus control, procedural efficiency, and versatility, BOBBY™ Balloon Guide Catheter – Reliable flow arrest with streamlined preparation, optimized compatibility and next-generation balloon technology, WEDGE™ Microcatheter – A navigation aid that minimizes ledge effect, HEADWAY™ Microcatheters – Low-profile outer diameter, providing versatility, reliability, and fast access, and TRAXCESS™ Guidewires – Soft-tip design for challenging anatomies.
お知らせ • May 28Terumo Interventional Systems, Division of Terumo Corporation, Announces Commercial Availability of its ROADSAVER Carotid Stent SystemTerumo Interventional Systems (TIS), a division of Terumo Corporation, announced the early commercial availability of its FDA-approved ROADSAVER Carotid Stent System. Indicated for use with the Nanoparasol®? Embolic Protection System, ROADSAVER Stent System addresses carotid artery stenosis in patients with increased risk of adverse events following carotid endarterectomy. ROADSAver Stent System is the only carotid artery stenting (CAS) device with an innovative, dual-layer micromesh. It is designed as a closed-cell stent with the flexibility of an open-cell stent, providing increased flexibility and wall apposition in complex anatomies. It is also the first dual-layer micromesh carotid stent approved in the United States, and the only carotid stent system designed to contain plaque to the vessel wall and prevent plaque protrusion, protecting against distal embolization. Available in sizes from 5 to 10 mm in width and 22 to 47 mm in length, ROADSAVER StENT System has a rapid-exchange shaft length of 143 cm. It is also fully re-sheathable and repositionable - even after 50% of the stent's length is deployed. Another important feature is the product's low-profile 5Fr design, which enhances its crossability. Limited market release of the ROADSAVER CarotID Stent System is planned for summer 2025, with full market release anticipated in fall 2025.
お知らせ • May 14Terumo Corporation, Annual General Meeting, Jun 24, 2025Terumo Corporation, Annual General Meeting, Jun 24, 2025.
お知らせ • Apr 17Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business OfficerTerumo Blood and Cell Technologies (Terumo BCT) announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments. Daly joins Terumo BCT with over 30 years of business and healthcare industry experience, both domestically and internationally. Most recently, he built the MedTech Global Data franchise at IQVIA, a provider of technology solutions to the life sciences industry. Daly has spent his career building commercial capabilities to deliver organic and inorganic growth. Before joining IQVIA, he was President and CEO of Cohera Medical, and he remains an independent Board Director for BioStem Technologies. He has held successive senior leadership roles in strategic marketing, sales and business development across various regions and businesses of Johnson &Johnson. He earned his Bachelor of Science in Foreign Area Studies from the U.S. Military Academy at West Point.
お知らせ • Mar 20Terumo Corporation to Report Fiscal Year 2025 Results on May 14, 2025Terumo Corporation announced that they will report fiscal year 2025 results on May 14, 2025
お知らせ • Dec 12Terumo Corporation to Report Q3, 2025 Results on Feb 13, 2025Terumo Corporation announced that they will report Q3, 2025 results on Feb 13, 2025
お知らせ • Dec 03Terumo Interventional Systems Announces Launch of Its R2p Navicross Peripheral Support CatheterTerumo Interventional Systems (TIS), a division of Terumo Corporation announced the launch and commercial availability of its R2P™ NaviCross® peripheral support catheter in the U.S., further expanding the company's radial-to-peripheral (R2P) portfolio. The R2P NaviCross catheter, now available in a 200 cm length, is designed for optimized performance in R2P procedures. Its double-braided, stainless-steel construction is engineered for superior trackability and torque control for lesion crossing in more complex procedures. The new 200 cm R2P NaviCross catheter rounds out the existing R2P portfolio, including the R2P Destination Slender™ guiding sheath, R2P SlenGuide™ guiding catheter, R2P Misago® self-expanding peripheral stent, and R2P Metacross™ RX and R2P Crosstella™ RX dilatation catheters – giving physicians the confidence to complete almost any PAD procedure from the wrist.
お知らせ • Sep 25Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024Terumo Corporation announced that they will report Q2, 2025 results on Nov 07, 2024
お知らせ • Aug 30Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million.Terumo Corporation (TSE:4543) announces a share repurchase program. Under the program, the company will repurchase up to 15,000,000 shares, representing 1.01% of its issued share capital, for ¥30,000 million. The purpose of the program is to increase shareholder returns, improve capital efficiency, and mitigate the impact on stock supply and demand associated with the offering of our common stock. The repurchased shares will be cancelled. The program will run until December 30, 2024. As of June 30, 2024, the company had 1,484,855,220 shares in issue (excluding treasury stock) and 5,842,060 shares in treasury.
お知らせ • Jun 03Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024Terumo Corporation announced that they will report Q1, 2025 results on Aug 08, 2024
お知らせ • May 29Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring SystemTerumo Cardiovascular announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the CDI OneView Monitoring System. The next-generation CDI Systems platform provides visibility of key patient parameters during cardiopulmonary bypass surgery, critical to perfusion safety and improving patient outcomes. The new CDI OneView System measures or displays up to 22 key parameters, the newest of which are measured flow (Q), cardiac index (CI), regional cerebral oxygen saturation (rSO2), oxygen extraction ratio (O2ER), Area Under the DO2 Curve (AUC), and measured arterial oxygen saturation (SaO2). This innovative system offers maximum configurability and flexibility in how the parameters can be viewed and prioritized to best suit clinical needs and preferences, while continuing to provide the critical information on which clinicians have come to rely. New features and functions of Terumo's latest patient parameter monitoring system were influenced by extensive perfusionist input from leading global cardiovascular institutions. In response to the growing needs of healthcare providers, the new CDI OneView System now provides real-time O2ER, CI, VO2 and DO2 information to help perfusionists maintain a safe threshold for those parameters. Independently published and reviewed clinical research indicates that maintaining optimal levels during cardiopulmonary bypass can help to reduce the incidence of acute kidney injury.
お知らせ • Mar 17Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024Terumo Corporation announced that they will report fiscal year 2024 results on May 14, 2024
お知らせ • Feb 09Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company expects revenue to be JPY 906,000 million. Operating profit to be JPY 140,000 million. Profit attributable to owners of parent to be JPY 105,000 million. Earnings per share to be JPY 141.18.
お知らせ • Feb 07Terumo Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation provided dividend guidance for the fiscal year ending March 31, 2024. For the year, the company expects dividend of JPY 22.00 per share against JPY 21.00 per share paid for the same period a year ago.
お知らせ • Dec 14+ 2 more updatesShinjiro Sato to Leave as CEO of Terumo Corporation on April 1, 2024Terumo Corporation announced that it has resolved at the Board of Directors held on December 14, 2023 to change the Executive Officers as. Shinjiro Sato's designation will be changed from President and CEO to the new position of Director and Corporate Advisor (As of April 1, 2024). Shinjiro Sato, with completion of his term, is planned to leave the director's position at the Annual General Meeting of Shareholders to be held on June 26, 2024, and to remain as corporate advisor.
お知らせ • Dec 03Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024Terumo Corporation announced that they will report Q3, 2024 results on Feb 07, 2024
お知らせ • Oct 01Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023Terumo Corporation announced that they will report Q2, 2024 results on Nov 14, 2023
お知らせ • Aug 10Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million.Terumo Corporation (TSE:4543) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 shares, representing 0.67% of its issued share capital, for ¥20,000 million. The purpose of the program is to expand shareholder returns and improve capital efficiency. The repurchased shares will be cancelled. The program will run until March 8, 2024. As of June 30, 2023, the company had 744,644,147 shares in issue (excluding treasury stock) and 3,038,393 shares in treasury.
お知らせ • Jun 21Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023Terumo Corporation announced that they will report Q1, 2024 results on Aug 09, 2023
お知らせ • May 17+ 1 more updateTerumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation announced fiscal year-end dividend of JPY 21.00 per share for the fiscal year ended March 31, 2023 against JPY 18.00 per share paid a year ago. Scheduled date to commence dividend payments is June 28, 2023.The company provided second quarter-end dividend guidance for the fiscal year ending March 31, 2024. For the second quarter-end, The company expects to pay JPY 22.00 against JPY 19.00 per share paid a year ago.The company provided year-end dividend guidance for the fiscal year ending March 31, 2024. For the year-end, The company expects to pay JPY 22.00 against JPY 21.00 per share a year ago.
お知らせ • May 16Terumo Corporation, Annual General Meeting, Jun 27, 2023Terumo Corporation, Annual General Meeting, Jun 27, 2023.
お知らせ • Feb 09Terumo Corporation Revises Dividend Guidance for Fiscal Year Ending March 31, 2023Terumo Corporation decided at the Board of Directors meeting held on February 9, 2023 to increase the year-end dividend forecast for fiscal year ending March 31, 2023. The details are as follows. The company revised dividend forecast to JPY 21.00 per share compared to the previous guidance of JPY 19.00 per share paid for the same period a year ago. Reason of the Revision: As a measure to secure high profit margins and sustainable growth, Terumo iscommitted to adequately and actively reinvesting its profits to enhance its corporate value continuously. As for the distribution of profits to shareholders, Terumo has been aiming to steadily increase its dividend payouts to shareholders with the target dividend payout ratio of 30% in the mid to long-term.
お知らせ • Nov 10Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023Terumo Corporation announced that they will report Q3, 2023 results on Nov 10, 2023
お知らせ • Aug 25Terumo Corporation (TSE:4543) acquired ReThink Medical, Inc.Terumo Corporation (TSE:4543) acquired ReThink Medical, Inc. on August 11, 2020. Hiroki Kobayashi of Latham & Watkins LLP acted as the legal advisor to Terumo. Terumo Corporation (TSE:4543) completed the acquisition of ReThink Medical, Inc. on August 11, 2020.
お知らせ • Jul 30Terumo Corporation (TSE:4543) acquired remaining 80.1% stake in Quirem Medical B.V. for $45 million.Terumo Corporation (TSE:4543) acquired remaining 80.1% stake in Quirem Medical B.V. for $45 million on July 15, 2020. Terumo will make a one-time, up-front payment of USD 20 million with up to USD 25 million additional payments based on the achievement of future milestones by 2030. It will be funded through cash on hand and will not significantly impact the company's financial projections for the current fiscal year ending March 31, 2021. Terumo Corporation (TSE:4543) completed the acquisition of remaining 80.1% stake in Quirem Medical B.V. on July 15, 2020.
お知らせ • Jun 29Terumo Corporation to Report Q1, 2021 Results on Aug 06, 2020Terumo Corporation announced that they will report Q1, 2021 results on Aug 06, 2020
